Skip to main content
J2KBIO Co., Ltd. logo

J2KBIO Co., Ltd. — Investor Relations & Filings

Ticker · 420570 ISIN · KR7420570004 KO Manufacturing
Open in API
Filings indexed 53 across all filing types
Latest filing 2024-01-05 Investor Presentation
Country KR South Korea
Listing KO 420570

About J2KBIO Co., Ltd.

https://www.j2kbio.com/eng/

J2KBIO Co., Ltd. is a research and development-focused bio-venture company that designs and develops active ingredients and sustainable raw materials. The company utilizes natural ingredients and microorganisms, employing advanced processes such as microbial fermentation and its proprietary METABIOME technology. Its research focuses on exploring the interactions between its ingredients and the skin to discover materials with optimal efficacy. The resulting bio-materials are supplied for use in a variety of sectors, including cosmetics, personal care products, functional foods, and household goods. The company is committed to developing safe and beneficial ingredients for skin application while promoting a sustainable coexistence between people and nature.

Recent filings

Filing Released Lang Actions
투자설명서
Investor Presentation Classification · 95% confidence The document is a '투자설명서' (Investment Prospectus) for J2K Bio, detailing a merger with a SPAC (Kyobo 11th SPAC). It contains comprehensive information regarding the merger, risk factors, financial data, and share issuance details. In the context of financial filings, a prospectus for a merger/offering is classified as a Proxy Solicitation & Information Statement (PSI) as it provides shareholders with the necessary information to evaluate the transaction and vote.
2024-01-05 Korean
[기재정정]증권신고서(합병)
M&A Activity Classification · 98% confidence The document is a '증권신고서(합병) 정정신고' (Amendment to Securities Registration Statement for Merger). It explicitly details corrections made to a previously filed merger registration statement, including updates to financial risk factors, business strategies, and employee data. In the context of financial filings, a Securities Registration Statement related to a merger is classified under M&A Activity (TAR) as it pertains to the regulatory documentation required for a merger or takeover bid.
2023-12-22 Korean
[기재정정]증권신고서(합병)
M&A Activity Classification · 98% confidence The document is a 'Correction Report' (정정신고서) for a 'Securities Registration Statement' (증권신고서) regarding a merger (합병) between J2K Bio and Kyobo 11th SPAC. It details specific amendments to the merger ratio, valuation, and financial projections. In the context of Korean financial filings (DART), a 'Securities Registration Statement' (증권신고서) is a regulatory filing that provides detailed information about a corporate action (like a merger). Since it is a formal regulatory filing document rather than a simple announcement of a report, it falls under the 'Regulatory Filings' category.
2023-12-18 Korean
증권신고서(합병)
M&A Activity Classification · 100% confidence The document is a '증권신고서(합병)' (Securities Registration Statement for Merger) filed by J2K Bio with the Financial Services Commission (FSC) in South Korea. It details the merger process with a SPAC (Kyobo 11th SPAC), including risk factors, financial information, and share issuance details. In the context of financial filings, a Securities Registration Statement for a merger is a primary regulatory document for corporate restructuring and capital changes, which falls under the 'Regulatory Filings' category as it is a formal legal filing required by the regulator.
2023-12-07 Korean
감사보고서 (2022.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for the company 'J2K Bio' (주식회사 제이투케이바이오) for the fiscal year ending December 31, 2022. It includes the independent auditor's report, financial statements (Balance Sheet, Income Statement, Statement of Changes in Equity, Cash Flow Statement), and detailed notes to the financial statements. This is a comprehensive financial document, not an announcement or a summary, and fits the definition of an Audit Report (AR). FY 2022
2023-04-06 Korean
연결감사보고서 (2022.12)
Annual Report Classification · 100% confidence The document is a comprehensive 'Consolidated Audit Report' (연결감사보고서) for J2K Bio, covering the fiscal year ending December 31, 2022. It includes the independent auditor's report, consolidated financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes to the financial statements. This constitutes a full annual financial report, which falls under the 'Annual Report' (10-K) category in the provided schema. FY 2022
2023-04-06 Korean

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.